Elanco raises 2026 revenue guidance to $5.09 billion-$5.14 billion from $5.01 billion-$5.085 billion
Company lifts 2026 adjusted EPS forecast to $1.10-$1.16 from $1.03-$1.09
Elanco expects Q3 revenue of $1.195 billion-$1.22 billion and adjusted EPS of $0.19-$0.22
Overview
U.S. animal health firm's Q2 revenue rose 10%, beating analyst expectations
Adjusted EPS for Q2 beat analyst expectations
Company raised full-year revenue and adjusted EPS guidance
Result drivers
New products - Zenrelia and Credelio Quattro were the largest contributors to global growth, per company statement
Pet health demand - U.S. Pet Health segment revenue rose, led by strong demand for innovative products
Favorable mix and pricing - Gross margin expansion was driven by favorable mix from U.S. Pet Health and increased pricing, partially offset by higher inventory costs
Analyst coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
ELAN•
